Adda Grimberg1,2,3, Anders Lindberg4, Michael Wajnrajch5,6, Andrew J Cucchiara7, Cecilia Camacho-Hübner5. 1. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3. Division of Pediatric Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 4. Biostatistics, Pfizer Health AB, Sollentuna, Sweden. 5. Pfizer Inc., New York, New York, USA. 6. Division of Pediatric Endocrinology, New York University School of Medicine, New York, New York, USA. 7. Center for Human Phenomics Science and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract
BACKGROUND/AIMS: To compare racial/ethnic proportions of subjects receiving growth hormone (GH) treatment to the expected proportions, and secondarily, to assess racial/ethnic differences in subject characteristics at GH treatment initiation. METHODS: Race/ethnicity-based expected frequencies of height <-2.25 SD were determined by applying relative risks for short stature, calculated from a regional population of 189,280 pediatric primary care patients, to US census data, and compared to racial/ethnic proportions of US subjects enrolled in the Pfizer International Growth Study (KIGS) using the χ2 test. Characteristics of white and black subjects at GH treatment initiation were presented as medians and compared by the Wilcoxon rank sum test (significant p < 0.01). RESULTS: White subjects exceeded the expected frequency (63%) for all indications (83%) and each separately, ranging from 73% for congenital GH deficiency (GHD) to 85% for idiopathic short stature (p < 0.001). Compared to white subjects, black subjects treated for idiopathic GHD had greater height deficits relative both to the population (-2.97 vs. -2.56 SD) and to their mid-parental heights (-2.47 vs. -1.89 SD), lower stimulated GH peak levels (4.9 vs. 6.0 ng/mL), and lower birth weights (-0.86 vs. -0.48 SD). Black subjects with congenital GHD had lower stimulated GH peaks (2.1 vs. 3.2 ng/mL) and started GH treatment at younger ages (2.9 vs. 4.8 years), while those with acquired GHD had lower birth weights (-1.12 vs. -0.08 SD). Male predominance did not differ by race for any or all indications. CONCLUSION: Overrepresentation of white children among those receiving GH treatment in the US KIGS registry reflects racial/ethnic treatment biases, not just differences in growth rates.
BACKGROUND/AIMS: To compare racial/ethnic proportions of subjects receiving growth hormone (GH) treatment to the expected proportions, and secondarily, to assess racial/ethnic differences in subject characteristics at GH treatment initiation. METHODS: Race/ethnicity-based expected frequencies of height <-2.25 SD were determined by applying relative risks for short stature, calculated from a regional population of 189,280 pediatric primary care patients, to US census data, and compared to racial/ethnic proportions of US subjects enrolled in the Pfizer International Growth Study (KIGS) using the χ2 test. Characteristics of white and black subjects at GH treatment initiation were presented as medians and compared by the Wilcoxon rank sum test (significant p < 0.01). RESULTS: White subjects exceeded the expected frequency (63%) for all indications (83%) and each separately, ranging from 73% for congenital GH deficiency (GHD) to 85% for idiopathic short stature (p < 0.001). Compared to white subjects, black subjects treated for idiopathic GHD had greater height deficits relative both to the population (-2.97 vs. -2.56 SD) and to their mid-parental heights (-2.47 vs. -1.89 SD), lower stimulated GH peak levels (4.9 vs. 6.0 ng/mL), and lower birth weights (-0.86 vs. -0.48 SD). Black subjects with congenital GHD had lower stimulated GH peaks (2.1 vs. 3.2 ng/mL) and started GH treatment at younger ages (2.9 vs. 4.8 years), while those with acquired GHD had lower birth weights (-1.12 vs. -0.08 SD). Male predominance did not differ by race for any or all indications. CONCLUSION: Overrepresentation of white children among those receiving GH treatment in the US KIGS registry reflects racial/ethnic treatment biases, not just differences in growth rates.
Authors: Shumei S Sun; Christine M Schubert; William Cameron Chumlea; Alex F Roche; Howard E Kulin; Peter A Lee; John H Himes; Alan S Ryan Journal: Pediatrics Date: 2002-11 Impact factor: 7.124
Authors: G P August; B M Lippe; S L Blethen; R G Rosenfeld; S A Seelig; A J Johanson; P G Compton; J W Frane; B H McClellan; B M Sherman Journal: J Pediatr Date: 1990-06 Impact factor: 4.406
Authors: Adda Grimberg; Lina Huerta-Saenz; Robert Grundmeier; Mark Jason Ramos; Susmita Pati; Andrew J Cucchiara; Virginia A Stallings Journal: Sci Rep Date: 2015-06-09 Impact factor: 4.379
Authors: Talia Hitt; Kenneth R Ginsburg; Pamela Cousounis; Terri H Lipman; Andrew J Cucchiara; Virginia A Stallings; Adda Grimberg Journal: Horm Res Paediatr Date: 2020-03-31 Impact factor: 2.852
Authors: Aristides K Maniatis; Mauri Carakushansky; Sonya Galcheva; Gnanagurudasan Prakasam; Larry A Fox; Adriana Dankovcikova; Jane Loftus; Andrew A Palladino; Maria de Los Angeles Resa; Carrie Turich Taylor; Mehul T Dattani; Jan Lebl Journal: J Endocr Soc Date: 2022-09-10
Authors: Luca Narduzzi; Corinne Buisson; Marie-Line Morvan; Alexandre Marchand; Michel Audran; Yves Le Bouc; Emmanuelle Varlet-Marie; Magnus Ericsson; Bruno Le Bizec; Gaud Dervilly Journal: Front Mol Biosci Date: 2021-06-10